Retatrutide (LY3437943) is a next-generation triple incretin receptor agonist that co-activates the GLP-1 receptor, GIP receptor, and glucagon receptor. The compound represents a new frontier in pharmacological research into metabolic disease, with a unique receptor activation profile that has produced markedly strong outcomes in clinical metabolic and glycemic research compared to preceding classes of incretin-based compounds. Researchers studying the mechanistic underpinnings of triple agonism, receptor crosstalk, and metabolic disease pathways continue to reference Retatrutide as a primary tool compound.

Retatrutide’s glucagon receptor agonism is a distinguishing feature from dual GLP-1/GIP agonists, providing a third mechanism of action that amplifies energy expenditure through hepatic and thermogenic pathways. In clinical and preclinical research, these combined mechanisms have been associated with changes in adipose tissue mass, liver lipid content, and cardiovascular risk markers. Studies have also examined Retatrutide’s effects on insulin secretion dynamics, beta-cell function, and appetite-regulating neuropeptide expression.

This 60mg high-concentration preparation is suited for extended preclinical research programs, multi-arm study designs, or large-animal model research requiring significant compound quantities. As one of the most clinically advanced triple incretin receptor agonists, Retatrutide is a key reference compound in metabolic disease pharmacology and research.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.